Utilization of targeted disease-modifying anti-rheumatic drugs (DMARDs) for managing rheumatoid arthritis in the last decade: A two-country comparison
Utilization of targeted disease-modifying anti-rheumatic drugs (DMARDs) for managing rheumatoid arthritis in the last decade: A two-country comparison
复制标题
DOI：
10.5414/cp203964
复制
发表时间：
2021-10-01
影响因子：
0.8
通讯作者：
Pratt, Nicole
中科院分区：
文献类型：
--
作者：
Park, So-Hee;Jeon, Ha-Lim;Pratt, Nicole
目的：比较韩国和澳大利亚在类风湿关节炎（RA）中靶向疾病改善抗风湿药物（DMARDs）的使用趋势。材料和方法：使用韩国和澳大利亚（2010 - 2018）的抽样索赔数据库，我们分析了两国使用个体靶向dmard（生物和靶向合成）治疗RA的趋势。结果：在澳大利亚和韩国，靶向dmard治疗RA的使用分别增加了200%和300%以上。肿瘤坏死因子抑制剂（tnfi）依那西普和阿达木单抗是2010年两国最常用的处方药，非tnfi的使用在研究期间有所增加。2015年，tofacitinib在韩国和澳大利亚的市场份额分别为10%和15%。结论：韩国和澳大利亚使用靶向dmard治疗RA的趋势相似，包括托法替尼在内的非tnfi药物的使用在这两个国家都有所增加。
Objective: To compare trends in the use of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA), between Korea and Australia. Materials and methods: Using sampled claims databases in Korea and Australia (2010 - 2018), we analyzed the trends in the use of individual targeted DMARDs (biologic and targeted synthetic) for RA in both countries. Results: The use of targeted DMARDs for the management of RA showed an increase of over 200 and 300% in Australia and Korea, respectively. The tumor necrosis factor inhibitors (TNFis) etanercept and adalimumab were the most commonly prescribed drugs in 2010 in both countries, with non-TNFi use increasing over the study period. The introduction of tofacitinib in 2015 led to 10 and 15% market share uptake in Korea and Australia, respectively. Conclusion: Trends in the use of targeted DMARDs for RA were similar in Korea and Australia, and the use of non-TNFis, including tofacitinib, increased in both countries.